{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-26-000049","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2026-06-16T20:15:07+00:00","discovered_at":"2026-06-16T20:16:01.367136+00:00","generated_at":"2026-06-16T20:16:13.447669+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Intensity Therapeutics stockholders elect directors, approve equity plan amendments at annual meeting","bullets":["Elected Dr. Emer Leahy and Lewis H. Bender as Class III directors with ~416,613 and ~422,149 votes for, respectively.","Ratified EisnerAmper LLP as auditor for FY 2026 with 1,024,971 votes for, 4,852 against.","Approved amendment to 2021 Stock Incentive Plan to increase shares by 150,000 (363,563 for, 69,252 against).","Approved amendment to 2024 ESPP to increase shares by 25,000 (407,404 for, 25,350 against).","Adjournment proposal passed with 939,304 votes for, 126,814 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-26-000049","json":"https://secwatch.observer/filing/0001567264-26-000049.json","markdown":"https://secwatch.observer/filing/0001567264-26-000049.md","text":"https://secwatch.observer/filing/0001567264-26-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000049/0001567264-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000049/intensity-20260616.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T20:16:13.447669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62da89c32c2ad3359e416eb29545027a0399412a","claim":"INTENSITY THERAPEUTICS, INC. shareholders approved Approval of amendment to 2024 Employee Stock Purchase Plan to increase shares available by 25,000 at the 2026-06-16 meeting.","evidence_excerpt":"For Against Abstain Broker Non-Votes 407,404 25,350 3,324 643,416","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000049/0001567264-26-000049-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"7a5d83d9baa6e7e334178e6cab103ef739369bc6","claim":"INTENSITY THERAPEUTICS, INC. shareholders approved Ratification of selection of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-16 meeting.","evidence_excerpt":"For Against Abstain 1,024,971 4,852 49,671","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000049/0001567264-26-000049-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"7c0f45e1ffe85926baa03eaed2ec430c44b12d98","claim":"INTENSITY THERAPEUTICS, INC. shareholders approved Approval of any postponement or adjournment of 2026 annual meeting, if necessary at the 2026-06-16 meeting.","evidence_excerpt":"For Against Abstain 939,304 126,814 13,376","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000049/0001567264-26-000049-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"91526386df279891a274c15e6b3503fdfe39b7c0","claim":"INTENSITY THERAPEUTICS, INC. shareholders approved Election of two Class III directors to hold office until the 2029 annual meeting at the 2026-06-16 meeting.","evidence_excerpt":"Nominee For Withheld Broker Non-Votes Dr. Emer Leahy 416,613 19,465 643,416 Lewis H. Bender 422,149 13,929 643,416","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000049/0001567264-26-000049-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"fb3b02457f99c20d4647b63ebf4ff9253088bdb2","claim":"INTENSITY THERAPEUTICS, INC. shareholders approved Approval of amendment to 2021 Stock Incentive Plan to increase shares available by 150,000 at the 2026-06-16 meeting.","evidence_excerpt":"For Against Abstain Broker Non-Votes 363,563 69,252 3,263 643,416","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000049/0001567264-26-000049-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}